Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

breakthrough therapy

- PMLiVE

Pfizer revenues decline in Q4 but profits surge

Lipitor patent loss continues to hit sales

- PMLiVE

Pfizer launches chronic pain forum

Twitter style comments are used to help patients describe their conditions

- PMLiVE

Takeda gets FDA approval for alogliptin franchise in diabetes

Comprises Nesina, Oseni and Kazano

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

NICE backs two cystic fibrosis treatments for NHS use

Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

Novartis building

Novartis expects tough 2013 before a return to growth

Says it will take a year for new medicine sales to overcome Diovan patent loss

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

Novartis day

Novartis gets EU approval for Bexsero meningitis B shot

Offers protection for all ages above two months

- PMLiVE

Novartis’ eye drug Jetrea recommended for EU approval

Set to become first drug treatment for sight-threatening condition vitreomacular traction and macular hole

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links